<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: October 19, 2000
Date of earliest event reported: October 10, 2000
AVIRON
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
<TABLE>
<S> <C>
0-20815 77-0309686
(Commission File No.) (IRS Employer Identification No.)
</TABLE>
297 N. BERNARDO AVENUE
MOUNTAIN VIEW, CA 94043
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 919-6500
-----------------------
<PAGE> 2
ITEM 5. OTHER EVENTS.
On October 11, 2000, Aviron announced that its United Kingdom subsidiary,
Aviron UK Ltd., had agreed to assume from CellTech Group Plc a 25-year lease,
covering approximately eight acres of land in Speke, United Kingdom. A term of
approximately 24 years remains under the lease.
Aviron also announced that it had entered into the Amended and Restated
Contract Manufacturing Agreement, dated October 10, 2000, between Aviron and
Evans Vaccines Limited, and other related agreements, providing for the
restructuring of services provided by Evans Vaccines to Aviron for the
manufacturing of FluMist(TM), Aviron's intranasal influenza vaccine, for a term
of approximately six years. Under the agreements, Aviron will have primary
responsibility of manufacturing FluMist(TM).
Additionally, Aviron concurrently announced that it had agreed to issue and
sell to Biotech Invest, S.A., four hundred fifty thousand (450,000) shares of
Common Stock of Aviron for the total aggregate price of $21.6 million, or $48.00
per share. The sale of the shares was subsequently consummated on October 12,
2000. Aviron has agreed to register these shares for resale in approximately six
months from the date of the issuance.
See press release attached hereto as Exhibit 99.1.
ITEM 7.EXHIBITS.
Exhibit 99.1 Press Release, dated October 11, 2000, entitled "Aviron
Strengthens FluMist(TM)Commercial Infrastructure With
Two Transactions In United Kingdom."
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
AVIRON
Dated: October 19, 2000 By: /s/ C. Boyd Clarke
--------------------
C. Boyd Clarke
President and Chief Executive Officer
<PAGE> 4
INDEX TO EXHIBITS
Exhibit 99.1 Press Release, dated October 11, 2000, entitled "Aviron
Strengthens FluMist(TM)Commercial Infrastructure With
Two Transactions In United Kingdom."
